This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Randomized Controlled Trial  • Psychopharmacology  • Drug Therapy  • Schizophrenia  • Alert me on articles by topic

Peter B. Jones, MD, PhD; Thomas R. E. Barnes, MD, DSc; Peter Elton, DPH; Linda Davies, MSc; Graham Dunn, PhD; Helen Lloyd, BA; Karen P. Hayhurst, MSc; Robin M. Murray, MD, DSc; Alison Marwick, BA; Shôn Lewis, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We are grateful to the correspondents for their careful consideration of data from CUtLASS 1,¹ and for making comparisons with CATIE and other major trials.

The characteristics of sulpiride and the use of depot drugs, mentioned by Andrade and Kharawala, were discussed in our article and we have nothing to add; sulpiride would have had to have been more atypical than the atypical antipsychotics to have accounted for our results. Mintz and Kopelowicz concentrate on all-cause discontinuations and switching between FGAs and SGAs. They identify evidence to support superiority of olanzapine over FGAs. This would be a reasonable hypothesis to test in a study designed for this purpose. However, we . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

First- vs Second-Generation Antipsychotic Drugs in Schizophrenia
Chittaranjan Andrade and Saifuddin Kharawala
Arch Gen Psychiatry. 2007;64(8):978-979.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Jeffrey A. Lieberman
Arch Gen Psychiatry. 2006;63(10):1069-1072.
EXTRACT | FULL TEXT  

Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Robert A. Rosenheck
Arch Gen Psychiatry. 2006;63(10):1074-1076.
EXTRACT | FULL TEXT  

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones, Thomas R. E. Barnes, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Markwick, and Shôn W. Lewis
Arch Gen Psychiatry. 2006;63(10):1079-1087.
ABSTRACT | FULL TEXT